Leaders from Amgen and Celltheon Set to Keynote BPI West

Specialists from every discipline and stage of development aim to achieve the common goals of optimizing speed, reducing cost, and improving quality from basic research to commercialization. What helps the learning curve is to benchmark best practices from the exclusive experience of the top minds in the biopharmaceutical industry.

The leading experts from Amgen and CellTheon will get together at BPI West in Oakland, CA (March 14-17, 2016) to share their exclusive case studies and new data and evaluate the different approaches that are being utilized to streamline and accelerate development and production across:

- Basic Research & Discovery
- Early Stage Process Development & Pre-Clinical Manufacturing
- Late Stage Process Development & Clinical Manufacturing
- Commercial Manufacturing & Beyond

The following keynotes have been announced:

Amita Goel, MSc. Founder, and CEO, Celltheon will be presenting on Innovative Technologies for the Expression of Next Generation Bio Therapeutics;

Rohini Deshpande, Ph.D. Executive Director, Process and Product Development, Amgen will give a talk on End-to-End Integration;

Ran Zheng, Ph.D., Executive Director, Plant Manager, Amgen is joining BPI West with a presentation called “Unleashing the Power of Innovation to Tackle Biomanufacturing's Greatest Challenges, Fuel Growth and Drive Value Creation.”

To see more speakers and to get the most up-to-date brochure, click here. 

Don’t miss the chance to learn the innovative strategies and technologies and help move the pipeline of next generation drug candidates closer to approval!

Register before Friday, January 22nd and save $400 – Simply use the code BPIWEST16BL, to save. 

Follow @Futurebiopharma

Share this article with your social network, just click below to share now!

Share |

Bruker Announces Industry Leading Quadrupole Time-of-Flight Mass Spectrometry for Life Science Research Analysis

WASHINGTON, DC – November 3, 2014 – Bruker Corporation (NASDAQ: BRKR) announced today, the evolution of their maXis™ line of ultrahigh-resolution quadrupole time-of-flight (UHR-qTOF) mass spectrometers, bringing industry-leading resolution and mass accuracy to the liquid chromatography, time-of-flight MS market space.  The system, announced at IBC’s 18th annual Well Characterized Biologicals Conference, is designed to deliver outstanding resolution and mass accuracy which allows for unambiguous identification of the mono-isotopic mass peak of both the light and heavy chains of monoclonal antibodies for example. In addition, this level of performance also provides scientists confident detection and identification of modifications hard to detect at the protein level, such as deamidation.

 “The maXis II system delivers the fastest time-to-success for life science researchers and across a broad range of applications from the in-depth identification and characterization of biopharmaceuticals and small molecule pharmaceuticals, to bottom-up proteomics and proteoform screening.” said Dr. Bob Galvin, Vice President of Bruker’s Biopharmaceutical Business Unit.  “Additionally, the system is well suited to research in the metabolomics, food safety, and forensic and toxicology screening markets as well.”

The maXis II™ – UHR-qTOF Mass Spectrometer

The new maXis II system is the latest flagship instrument in Bruker’s unique TOF mass spectrometry product line, allowing the simultaneous analysis of small molecules and megadalton proteins on one analytical platform.  The system delivers:

• Industry-leading (>80,000) Full-Sensitivity Resolution (FSR) at UPLC acquisition speeds thus enabling Bruker’s unique and  industry acknowledged True Isotopic Pattern spectral acquisition.  This allows for the  identification of the mono-isotopic mass peak of both the light and heavy chains of monoclonal antibodies or, when linked to Smart Formula 3D provides unambiguous elemental formula determination for the pharmaceutical and related  industries

• A High Mass Option (HMO) yieldingnative spray MS capabilities  provides enhanced analytical performance levels, particularly suited for biopharmaceutical and pharmaceutical challenges, like the analysis of megadalton protein complexes and  determination of antibody drug conjugates (ADCs). 

• The Electron Transfer Dissociation (ETD) option provides a powerful additional MS/MS fragmentation technique for the sequence analysis of intact proteins including monoclonal antibody subunits.  The  ETD MS/MS fragmentation technique is complimentary to collision induced dissociation (CID) MS/MS, yielding greater sequence coverage for proteins and providing additional capabilities to the new system.


Ordering Information
   
The maXis II mass spectrometer is available immediately. Please contact your local Bruker Sales Representative for a quote.

About Bruker Corporation

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information about Bruker Corporation (NASDAQ: BRKR), please visit www.bruker.com.



Media Contact:
Tony Lewtas               
Bruker Corporation           
T: +1 978 663 3660  ext.1212 
E: tony.lewtas@bruker.com          

Investor Contact:
Joshua Young
Vice President of Investor Relations, Bruker Corporation
T: +1 978 663 3660  ext.1479
E: joshua.young@bruker.com

Share this article with your social network, just click below to share now!

Share |

How can you achieve better integration for a biopharmaceutical firm?

Last week, BioProcess International conference producer Barry Walsh shared some of the newest emerging trends and technologies in biopharmaceutical production.  This week, Michael Keenan shares how these things can be better integrated into an organization to ensure that processes are better and more fluidly completed within the organization.  How does producer Michael Keenan think BioProcess International can do this?

How is this need for better integration at all process interfaces within the organization.being addressed and facilitated at the event?

As we were doing research for the event this year, we were really hearing from a lot of people a very common theme, which is how do we break down the barriers between process development and manufacturing and even within process development? Breaking down barriers between upstream and downstream, breaking down barriers between clinical and commercial manufacturing? Even breaking down barriers between discovery up to sort of process development, really trying to make the transitions more smooth and efficient.

So, one of the ways that we tried to create a more integrated program agenda this year was by creating the concurrent conference tracks in such a way that whether you are in upstream development or downstream development, formulations, delivery, analytical quality or manufacturing, there were opportunities throughout the program for you to get specific content related to your specific interest, but yet jump to another track or another session to give you an idea of what happens before your job or after your job to help you integrate.

We have shared sessions this year. I know the upstream and downstream track have their sort of track, but we bring them together for an integrated upstream and downstream session so that both of those groups can understand and learn from each other. We have plenary sessions with fantastic keynote speakers this year, from Amgen, Genzyme, 11 biotherapeutics, Bristol Myers Squibb then Novartis on a variety of topics that will bring the entire audience together for a real keynote session and sharing of information and integration of ideas.
For the analytical quality track and the formulation development track and the manufacturing track, we also have brought those together for a shared session on one of the mornings again to facilitate this interaction and inter-discussion so that people from different disciplines can really learn from each other throughout the program.

This is an excerpt from a podcast interviews series in coordination with BPI Magazine.  To hear the complete podcast along with other speaker interviews, download them by visiting this webpage.



Next week, we'll hear from producer Michael Keenan on how he and Barry have worked to tailor the program to reach the needs of the new, emerging trends in the industry.

If you'd like to join Barry in Boston this coming September 16-19 at the Bioprocess International Conference, as a reader of this blog when you register to join us and mention code BLOG13JP, you'll save 20% off the standard rate! Have any questions? Feel free to email Jennifer Pereira.

Share this article with your social network, just click below to share now!

Share |